Models for human cervical cancer

Drug Discovery Today: Disease Models

Volumn 2, Issue 1, 2005, Pages 15-20

  Lambert, Paul F ^a   Brake, Tiffany ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; ESTRADIOL; ESTROGEN; RETINOIC ACID; VIRUS DNA; VIRUS PROTEIN;

CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PREVENTION; DRUG TARGETING; MOUSE STRAIN; NONHUMAN; REVIEW; TRANSGENIC MOUSE; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS ONCOGENE; VIRUS STRAIN; WART VIRUS;

EID: 21644462995     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2005.05.021     Document Type: Review

References (65)

1. D.M. Parkin et al. Cancer burden in the year 2000 Eur. J. Cancer 37 2001 S4-S66
2. L. Koutsky Epidemiology of genital human papillomavirus infection Am. J. Med. 102 1997 3-8
3. W. Cates Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel Sex. Transm. Dis. 26 1999 S2-S7
4. Cogliano, V. et al. Human papillomaviruses. Lancet Oncol. (in press)
5. D.M. Harper et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial Lancet 364 2004 1757-1765
6. D.R. Brown et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine Vaccine 22 2004 2936-2942
7. L.A. Koutsky et al. A controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 2002 1645-1651
8. S. Jeon et al. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells J. Virol. 69 1995 2989-2997
9. N. Dyson et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product Science 243 1989 934-937
10. B.A. Werness et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53 Science 248 1990 76-79
11. M. Scheffner et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc. Natl. Acad. Sci. USA 88 1991 5523-5527
12. E.S. Hwang et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene J. Virol. 67 1993 3720-3729
13. K. Munger et al. Human papillomavirus immortalization and transformation functions Virus Res. 89 2002 213-228
14. T. Crook et al. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells Proc. Natl. Acad. Sci. USA 85 1988 8820-8824
15. G. Matlashewski et al. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells EMBO J. 6 1987 1741-1746
16. W.C. Phelps et al. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A Cell 53 1988 539-547
17. V. Band et al. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements Proc. Natl. Acad. Sci. USA 87 1990 463-467
18. M. Durst et al. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA Oncogene 1 1987 251-256
19. P. Hawley-Nelson et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes EMBO J. 8 1989 3905-3910
20. P. Kaur et al. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/ E7 open reading frames J. Gen. Virol. 1989
21. L. Pirisi et al. Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA Carcinogenesis 9 1988 1573-1579
22. C.D. Woodworth et al. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA Cancer Res. 48 1988 4620-4628
23. T. Kiyono et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells see comments Nature 396 1998 84-88
24. A.J. Klingelhutz et al. Telomerase activation by the E6 gene product of human papillomavirus type 16 Nature 380 1996 79-82
25. B. Fu Keratinocyte et al. growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes Cancer Res. 63 2003 7815-7824
26. S. Dalal et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells J. Virol. 70 1996 683-688
27. H.R. McMurray et al. Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7 J. Virol. 78 2004 5698-5706
28. C.A. Reznikoff et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells Genes Dev. 8 1994 2227-2240
29. A.E. White et al. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins Genes Dev. 8 1994 666-677
30. J.T. Thomas et al. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint J. Virol. 72 1998 1131-1137
31. D.A. Thompson et al. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints Oncogene 15 1997 3025-3035
32. P.A. Havre et al. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells Cancer Res. 55 1995 4420-4424
33. S. Duensing et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle Proc. Natl. Acad. Sci. USA 97 2000 10002-10007
34. S. Duensing et al. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype Cancer Res. 61 2001 2356-2360
35. S. Duensing et al. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes J. Virol. 75 2001 7712-7716
36. T.D. Kessis et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage Proc. Natl. Acad. Sci. USA 90 1993 3988-3992
37. R.J. Slebos et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein Proc. Natl. Acad. Sci. USA 91 1994 5320-5324
38. G.W. Demers et al. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation J. Virol. 70 1996 6862-6869
39. S. Song et al. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53- independent pathways Proc. Natl. Acad. Sci. USA 95 1998 2290-2295
40. J.O. Funk et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein Genes Dev. 11 1997 2090-2100
41. D.L. Jones et al. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2 Genes Dev. 11 1997 2101-2111
42. A. Helt et al. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells J. Virol. 76 2002 10559-10568
43. T. Sasagawa et al. Induction of uterine cervical neoplasias in mice by human papillomavirus type 16 E6/E7 genes Cancer Res. 52 1992 4420-4426
44. J.M. Arbeit et al. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice Proc. Natl. Acad. Sci. USA 93 1996 2930-2935
45. D.A. Elson et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis Cancer Res. 60 2000 1267-1275
46. R. Riley et al. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis Cancer Res. 63 2003 4862-4871
47. S. Song et al. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis Virology 267 2000 141-150
48. T. Brake et al. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model Proc. Natl. Acad. Sci. USA 102 2005 2490-2495
49. V. Moreno et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study Lancet 359 2002 1085-1092
50. N. Munoz et al. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study Lancet 359 2002 1093-1101
51. T. Brake et al. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: Identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer Cancer Res. 63 2003 8173-8180
52. R. Herber et al. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene J. Virol. 70 1996 1873-1881
53. S. Song et al. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals J. Virol. 73 1999 5887-5893
54. I.H. Frazer et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure J. Immunol. 167 2001 6180-6187
55. K. Matsumoto et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors J. Natl. Cancer. Inst. 96 2004 1611-1619
56. J. Marx Medicine. Building better mouse models for studying cancer Science 299 2003 1972-1975
57. J.I. Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br. J. Cancer 84 2001 1424-1431
58. A.F. Frijhoff et al. Advances in molecular carcinogenesis: Current and future use of mouse models to screen and validate molecularly targeted anticancer drugs Mol. Carcinog. 39 2004 183-194
59. T. Van Dyke et al. Cancer modeling in the modern era: Progress and challenges Cell 108 2002 135-144
60. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins Proc. Natl. Acad. Sci. USA 97 2000 10173-10178
61. V. Lallemand-Breitenbach et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukaemia J. Exp. Med. 189 1999 1043-1052
62. R.F. Jacoby et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis Cancer Res. 60 2000 5040-5044
63. F. Yuan et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: Implication for prevention of cervical cancer Anticancer Res. 19 1999 1673-1680
64. K.J. Auborn et al. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis Intl. J. Cancer 49 1991 867-869
65. M.C. Bell et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN Gynecol. Oncol. 78 2000 123-129